Figure 4.

Decision tree representing only combinations of parameters where a majority was achieved.

Cabo, cabozantinib; CI, contraindication; ICI, immune checkpoint inhibitors; Ipi/Nivo, ipilimumab/nivolumab; mccRCC, metastatic renal cell carcinoma; Paz, pazopanib; Pembro/Axi, pembrolizumab/axitinib; Sun, sunitinib; Tivo, tivozanib. A, Paris, France; B, Vienna, Austria; C, Boston, USA; D, London, UK; E, Essen, Germany; F, Nashville, USA; G, New York, USA; H, Oslo, Norway; I, Cambridge, UK; J, Bari, Italy; K, St. Gallen, Switzerland.